AZN

AZN

USD

AstraZeneca PLC American Depositary Shares

$82.030+1.380 (1.711%)

Reaalajas hind

Healthcare
Drug Manufacturers - General
Ühendkuningriik

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$80.650

Kõrge

$82.110

Madal

$80.480

Maht

5.34M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

255.3B

Tööstusharu

Drug Manufacturers - General

Riik

United Kingdom

Kauplemisstatistika

Keskmine maht

4.52M

Börs

NMS

Valuuta

USD

52 nädala vahemik

Madal $61.24Praegune $82.030Kõrge $86.57

Seotud uudised

BusinessWire

DESTINY-Lung06 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic Non-Squamous Non-Small Cell Lung Cancer

The first patient has been dosed in the DESTINY-Lung06 phase 3 trial evaluating ENHERTU® (trastuzumab deruxtecan) plus pembrolizumab versus pembrolizumab, platinum-based chemotherapy and pemetrexed as a first-line

Vaata rohkem
DESTINY-Lung06 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic Non-Squamous Non-Small Cell Lung Cancer
CNBC

ServiceNow CEO denies AI companies are threatening enterprise software: 'They don't do what we do'

ServiceNow CEO Bill McDermott pushed back against the idea that artificial intelligence technology will make enterprise software redundant.

Vaata rohkem
ServiceNow CEO denies AI companies are threatening enterprise software: 'They don't do what we do'
CNBC

Eli Lilly, Walmart to offer first retail pickup option for discounted vials of weight loss drug Zepbound

Starting in mid-November, cash-paying patients can purchase Zepbound vials at discounts of 50% or more through the retailer's locations or via home delivery.

Vaata rohkem
Eli Lilly, Walmart to offer first retail pickup option for discounted vials of weight loss drug Zepbound

Püsi kursis

Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.